Anormed, Inc.

Genzyme Corporation

Ablynx N.v.

Toray Industries, Inc.

Dominique Schols

Gary James Bridger

David Earl Bogucki

Renato Skerlj

Ernest John McEachern

Curtis Harwig

Al Kaller

Yuanxi Zhou

Jason B Crawford

Trevor R Wilson

Siqiao Nan

Bem Atsma

Christopher Dennis Smith

Maria Rosaria Di Fluri

Eva Maria Boehringer

Zhongren Wang

Peter Vanlandschoot

Yongbao Zhu

Gang Chen

Ian R Baird

Renato Tony Skerlj

Bern Atsma

Christopher Dennis

Rosaria Maria Di Fluri

Krystyna Skupinska

Ernest J Mceachern

Johannes Joseph Wilhelmus De Haard

Michael John Scott Saunders

Christophe Blanchetot

Catelijne Stortelers

Peter Verheesen

Regorius Leurs

Philippe Van Rompaey

Martine Smit

Sven Jähnichen

Hugo Soares

Masanori Baba

Jan Balzarini

Stephanie Staelens

Markus Metz

Erik De Clercq

Annelies Roobrouck

Rudi Pauwels

Maria Rosario DiFluri

Renato T Skelj

Miguel Conde

Renato T Skerlj

Trevor Wilson

Siquiao Nan

The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.

Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity

The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Chemokine receptor binding heterocyclic compounds with enhanced efficacy

The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. Nanobodies specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. Amino acid sequences of the present invention may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.

Amino acid sequences directed against cellular receptors for viruses and bacteria

The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. NANOBODIES specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.

The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R, Rand Rare substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.

CXCR4 chemokine receptor binding compounds

Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.

Chemokine receptor binding heterocyclic compounds

The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.

CXCR4 antagonists

Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCRreceptor.

Compounds that interact with the CXCR4 receptor are described. These compounds are useful in treating, for Example, HIV infection and inflammatory conditions such as rheumatoid arthritis, as well as asthma or cancer, and are useful in methods to elevate progenitor and stem cell counts as well as methods to elevate white blood cell counts.

Methods to modulate conditions mediated by the CXCR4 receptor

Tertiary amine compounds that bind chemokine receptors such as CXCR4 and CCR5 are disclosed.

Growing community of inventors

Herent, Belgium

Dominique Schols